Blueprint Medicines

Blueprint Medicines

Blueprint Medicines

Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers
Founded
2011
Raised
$240M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$125,000,000
Post-IPO debt - 2016
Team Size
10+
Employees
$125,000,000 Post-IPO debt
Twitter

Biotech Day on Twitter

Xconomy

Blueprint, Roche Ink Milestone Deal for Cancer Immunotherapy

Health Science